Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Account Payables
Amounts the company owes suppliers for goods and services received.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 26.2% from a year ago
Account payables stood at $2.51M at the end of Q1 FY2026, down 26.2% from a year earlier and up 198.3% from the prior quarter. Over 3 fiscal years it compounded at -31.9% a year.
Context
- Account payables amounted to 0.6% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Account payables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -26.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 841K USD
- Year-over-year change
- -50.0%
- 4-year CAGR
- -28.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 841K | -50.0% |
| FY2024 | 2024-12-31 | 1.68M | -32.5% |
| FY2023 | 2023-12-31 | 2.49M | -6.3% |
| FY2022 | 2022-12-31 | 2.66M | -16.1% |
| FY2021 | 2021-12-31 | 3.17M | — |
Account Payables vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -26.2% is the 6th highest of 11, against a peer median of -15.9%.
- Account payables amounts to 0.6% of total assets for CGEM, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $72M USD | -29.7% | +36.8% | 4.3% | |
| Aug 2026 | $32.98M USD | +283.1% | +30.3% | 2.8% | |
| Jun 2026 | $12.65M USD | -31.8% | +2.4% | 1.7% | |
| Mar 2026 | $8.73M USD | +100.0% | +24.2% | 2.5% | |
| Mar 2026 | €8.06M EUR | +37.6% | -56.1% | 1.5% | |
| Mar 2026 | $5.3M USD | -66.0% | -9.4% | 1.8% | |
| Mar 2026 | $4.29M USD | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $3.85M USD | -2.1% | -15.3% | 2.2% | |
| Mar 2026 | $3.38M USD | +43.6% | +32.0% | 0.3% | |
| Mar 2026 | $2.53M USD | -76.9% | +9.9% | 1.7% | |
| Mar 2026 | $2.51M USD | -26.2% | -31.9% | 0.6% | |
| Peer median (excluding CGEM) | — | -15.9% | +6.1% | 1.9% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59.77M | 156.15M | 98.43M | 83.01M | 88.33M |
| Short-term Investments | 230.69M | 311.14M | 368.63M | 315.97M | 289.56M |
| Net Receivables | 0 | 0 | 0 | 3M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.18M | 13.12M | 12.69M | 8.86M |
| Total Current Assets | 296.56M | 474.47M | 480.19M | 414.67M | 386.76M |
| Property, Plant & Equipment (Net) | 77K | 5.3M | 3.53M | 2.35M | 3.05M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 140.4M | 80.88M | 0 | 204.44M | 58.27M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 147K | 459K | 459K | 366K | 297K |
| Total Non-current Assets | 140.62M | 86.65M | 3.99M | 207.16M | 61.62M |
| Total Assets | 437.19M | 561.12M | 484.18M | 621.82M | 448.37M |
| Account Payables | 3.17M | 2.66M | 2.49M | 1.68M | 841K |
| Short-term Debt | 0 | 178K | 0 | 0 | 0 |
| Tax Payables | 0 | 4.28M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.55M | 1.96M | 7.9M | 1.44M | 10.95M |
| Total Current Liabilities | 11.75M | 22.5M | 28.14M | 30.65M | 37.74M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.9M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 65K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 65K | 3.59M | 2.15M | 849K | 1.9M |
| Total Liabilities | 11.81M | 26.09M | 30.29M | 31.5M | 39.64M |
| Common Stock | 4K | 5K | 4K | 6K | 6K |
| Retained Earnings | (158.91M) | (47.7M) | (200.86M) | (368.24M) | (588.12M) |
| Accumulated OCI | (838K) | (2.6M) | (129K) | (133K) | 1.02M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 403K | 0 | 192K | 0 | 0 |
| Total Equity | 425.37M | 535.03M | 453.9M | 590.33M | 408.73M |
| Total Debt | 0 | 5.19M | 3.59M | 2.15M | 2.68M |
| Net Debt | (59.77M) | (150.96M) | (94.84M) | (80.85M) | (85.65M) |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.